Recombinant Human TWEAK
 
Catalog Number:
AF-310-06
Synonyms:
TNF-related weak inducer of apoptosis,  TNFSF12,  DR3LG,  Apo3-Ligand
Description:
TWEAK belongs to the TNF family of ligands and signals through TWEAKR also known as TNFRSF12A.  TWEAK is expressed in a variety of tissues, including the adult heart, pancreas, skeletal muscle, small intestine, spleen and peripheral blood lymphocytes.  TWEAK has the ability to induce NFkB activation and chemokine secretion, and to exert an apoptotic activity in certain cells, such as HT-29 human adenocarcinoma cells when cultured in the presence of IFN-g.  TWEAK also promotes proliferation and migration of endothelial cells.  Recombinant human TWEAK is a soluble 17.0 kDa polypeptide (154 amino acid residues) comprising the TNF homologous region of TWEAK and is generated by proteolytic processing of the full length membrane anchored TWEAK protein. Manufactured using all non-animal reagents.
AA Sequence:
MKGRKTRARR AIAAHYEVHP RPGQDGAQAG VDGTVSGWEE ARINSSSPLR YNRQIGEFIV TRAGLYYLYC QVHFDEGKAV YLKLDLLVDG VLALRCLEEF SATAASSLGP QLRLCQVSGL LALRPGSSLR IRTLPWAHLK AAPFLTYFGL FQVH
Source:
E.coli
Purity:
Greater than 98% by SDS-PAGE gel and HPLC analyses.
Biological Activity:
Assay #1:  The ED50 as determined by the dose-dependent stimulation of IL-8 production by human PBMC is less than 10 ng/ml.  
Assay #2:  TWEAK weakly induces the death of HT29 cells when cultured in the presence of IFN-γ.  The ED50 for this effect is between 30-45 ng/ml.
 
 
 
 
Research Interests:
Angiogenesis/ Cardiovascular
Apoptosis
Inflammation
Neurobiology
Proliferation
TNF Superfamily
 
 
Country of Origin:
USA
Research Use Only. Not for use in diagnostic or therapeutic procedures.